Skip to main content
SpringerLink
Log in

Mediatorblockade in der Sepsis: Inhibitoren, Antagonisten und Antikörper

  • Chapter
Intensivtherapie bei Sepsis und Multiorganversagen

Zusammenfassung

Gemäß den grundlegenden Ausführungen zur Definition der Sepsis in Kap. 1 steht die systemische Einschwemmung von Mikroben (in der Regel Bakterien oder Pilze) und/oder mikrobiellen Produkten am Anfang der pathophysiologischen Abläufe der Sepsis (Abb. 9-1). Unter den bakteriellen Toxinen haben die Endotoxine gram-negativer Bakterien besondere Beachtung gefunden (Tabelle 9-1). Ihr pathogenetisches Prinzip ist die allen Endotoxinen gemeinsame Lipid-A-Struktur, durch deren beobachtungen am Menschen eine Vielzahl typischer Charakteristika einer Sepsis reproduzieren lassen. Zahlreiche Untersuchungen zur Wirkung des Lipid A haben jedoch gezeigt, daß die meisten (wenn nicht alle) Effekte dieses bakteriellen Agens nicht aus einer „direkt-zytotoxischen“ Wirkung resultieren, sondern mittels Aktivierung körpereigener Mediatorkaskaden und inflammatorisch kompetenter Zellen induziert werden [6, 41].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abraham E, Wunderink R et al., and the TNF-a Mab sepsis study group (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273: 934–941

    Google Scholar 

  2. Austin OM, Redmond HP, Watson WG, Cunney RJ, Grace PA, Bouchier Hayes D (1995) The beneficial effects of immunostimulation in posttraumatic sepsis. J Surg Res 59: 446–449

    Article  PubMed  CAS  Google Scholar 

  3. Bernard GR, Reines HD, Halushka PV et al. (1991) Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Am Rev Respir Dis 144: 1095–1101

    Article  PubMed  CAS  Google Scholar 

  4. Bernard GR, Wheeler AP, Russell et al., the ibuprofen in sepsis study group (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336(13): 912–918

    Google Scholar 

  5. Bhakdi S, Tranum-Jensen J (1991) Alpha-toxin of Staphylococcus aureus. Microbiol Rev 55: 733–751

    PubMed  CAS  Google Scholar 

  6. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115: 457–469

    PubMed  CAS  Google Scholar 

  7. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–58

    Article  PubMed  CAS  Google Scholar 

  8. Briegel J, Kellermann W, Forst H et al. (1994) Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The phospholipase A2 study group. Clin Invest Med 72: 782–787

    CAS  Google Scholar 

  9. Brigham KL (1991) Oxygen radicals–an important mediator of sepsis and septic shock. Klin Wochenschr 69: 1004–1008

    Article  PubMed  CAS  Google Scholar 

  10. Buck C, Bundschu J, Gallati H, Bartmann P, Pohlandt F (1994) Interleukin-6: A sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics 93: 54–58

    Google Scholar 

  11. Cobb JP, Natanson C, Hoffman WD et al. (1992) N(omega)-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 176: 1175

    Article  PubMed  CAS  Google Scholar 

  12. Damas P, Ledous D, Monique YS, Vrindts Y, De Groote D, Franchimont P, Lamy M (1991) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215: 356–362

    Article  Google Scholar 

  13. Demaria A, Craven DE, Heffernan JJ, McIntosh TK, Grindlinger GA, McCabe WR (1985) Naloxone vs. placebo in treatment of septic shock. Lancet I: 1363–1365

    Google Scholar 

  14. Demitri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808

    Google Scholar 

  15. Dhainaut JFA, Vincent JL, Richard C et al., the CDP571 sepsis study group (1995) CDP571, a humanized antibody to human tumor necrosis factor-a: safety, pharmacokinetics, immune response, and influence of the anti-body on cytokine concentrations in patients with septic shock. Crit Care Med 23: 1461–1469

    Google Scholar 

  16. Dripps DJ, Verderber EV, Thompson RC, Eisenberg SP (1991) Interleukin-1 receptor antagonist binds to the type II receptor on B cells and neutrophils. J Biol Chem 266: 20311–20315

    PubMed  CAS  Google Scholar 

  17. Dunne JR, Dunkin BJ, Nelson S, White JC (1996) Effects of granulocyte colony stimulating factor in a nonneutropenic rodent model of Escherichia coli peritonitis. J Surg Res 61: 348–354

    Article  PubMed  CAS  Google Scholar 

  18. Echternacher B, Falk W, Mannel DN, Krammer PH (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145: 3762–3766

    Google Scholar 

  19. Faist E, Schinkel C, Zimmer S (1996) Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 20: 454–459

    Article  PubMed  CAS  Google Scholar 

  20. Fischer E, Marano MA, VanZee KJ et al (1992) Interleukin-1 receptor blockade improves survival hemodynamic performance in E. coli septic shock but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551–1557

    CAS  Google Scholar 

  21. Fischer E, Marano MA, Barber AE et al (1991) A comparison between the effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am J Physiol 261: 442–452

    Google Scholar 

  22. Fisher CJ, Opal SM, Dhainaut JF et al., the CB0006 sepsis syndrome study group (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 21: 318–327

    Google Scholar 

  23. Fisher JF, Dhainaut JFA, Opal SM et al., the phase III rhIL-la sepsis syndrome study group (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271: 1836–1842

    Google Scholar 

  24. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol, WM (1991) Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83: 2038–2047

    Google Scholar 

  25. Görgen I, Hartung T, Leist M et al. (1992) Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-a. J Immunol 149: 918–924

    PubMed  Google Scholar 

  26. Goldie AS, Fearon KCH, Ross JA et al., the sepsis intervention group (1995) Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274: 172–177

    Google Scholar 

  27. Grimminger F, Seeger W (1990) Regulation inflammatorischer Abläufe–Angriffspunkte and Grenzen steroidaler Antiphlogistika. Med Welt 41: 951–964

    Google Scholar 

  28. Grimminger F, Sibelius U, Bhakdi S, Suttorp N, Seeger W (1991) Escherichia coli hemolysin is a potent inductor of phosphoinositide hydrolysis and related metabolic responses in human neutrophils. J Clin Invest 88: 1531–1539

    Google Scholar 

  29. Grimminger F, Walmrath D, Seeger W, Lasch H-G (1993) Parenterale omega 3-Lipidbehandlung bei inflammatorischen Systemerkrankungen–experimentelle and klinische Befunde. Med Welt 44: 207–216

    Google Scholar 

  30. Kox WJ, Bone RC, Krausch D et al. (1997) Interferon Gamma 1B in the treatment of compensatory anti-inflammatory response syndrome: A new approach: Proof of principle. Arch Intern Med 157: 389–393

    Google Scholar 

  31. Lefering R, Neugebauer EAM (1995) Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 23: 1294–1303

    Article  PubMed  CAS  Google Scholar 

  32. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF (1988) Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 138: 62–68

    Article  PubMed  CAS  Google Scholar 

  33. Lundblad R, Nesland JM, Giercksky KE (1996) Granulocyte colony-stimulating factor improves survival rate and reduces concentrations of bacteria, endotoxin, tumor necrosis factor, and endothelin-1 in fulminant intra-abdominal sepsis in rats. Crit Care Med 24: 820–826

    Article  PubMed  CAS  Google Scholar 

  34. Mandell GL (1988) ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis 138: 1103–1105

    PubMed  CAS  Google Scholar 

  35. Nava E, Palmer RM, Moncada S (1991) Inhibition of nitric oxide synthesis in septic shock: how much is beneficial?. Lancet 338: 1555–1557

    Article  PubMed  CAS  Google Scholar 

  36. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MRB (1994) Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 81: 1306–1308

    Article  PubMed  CAS  Google Scholar 

  37. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD (1995) Mechanism of endotoxin desensitization: Involvement of interleukin 10 and transforming growth factor beta. J Exp Med 181: 1887–1892

    Article  PubMed  CAS  Google Scholar 

  38. Reinhart K, Wiegand-Löhnert C, Grimminger F et al.,the MAK 195 F sepsis study group (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733–742

    Google Scholar 

  39. Seeger W (1992) Behandlung des ARDS–Gesicherte Konzepte and therapeutische Perspektiven. Intensivmedizin 29: 201–218

    Google Scholar 

  40. Seeger W, Lasch HG (1987) Septic lung. Rev Infect Dis 9: 570–579

    Article  Google Scholar 

  41. Seeger W, Lasch HG (1988) Pathophysiologie der Sepsis. Intern Welt 10: 260–267

    Google Scholar 

  42. Seeger W, Lasch HG (1990) Pathogenese and Klinik der Sepsis. Arzt and Krankenhaus 5: 133–143

    Google Scholar 

  43. Sheppard BC, Fraker DL, Norton JA (1989) Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 106: 156–160

    PubMed  CAS  Google Scholar 

  44. Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE (1995) Granulocyte colony-stimulating factor vs. placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 86: 1301–1309

    PubMed  CAS  Google Scholar 

  45. Sprung CL, Caralis PV, Marcial EH et al. (1984) The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 311: 1137–1143

    Article  PubMed  CAS  Google Scholar 

  46. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317: 659–665

    Article  Google Scholar 

  47. Zabel P, Wolter DT, Schönharting MM, Schade FU (1989) Oxpentifylline in endotoxinemia. Lancet 334: 1474 1477

    Google Scholar 

Download references

Authors
  1. W. Seeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Grimminger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Walmrath
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Städt. Krankenhaus Hildesheim Lehrkrankenhaus, Medizinischen Hochschule Hannover, Weinberg 1, 31134, Hildesheim, Deutschland

    Hans-Peter Schuster

  2. Klinikum Kröllwitz/Innere Medizin II, Martin-Luther-Universität, Ernst-Grube-Str. 40, 06097, Halle /Saale, Deutschland

    Karl Werdan

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Seeger, W., Grimminger, F., Walmrath, D. (2000). Mediatorblockade in der Sepsis: Inhibitoren, Antagonisten und Antikörper. In: Schuster, HP., Werdan, K. (eds) Intensivtherapie bei Sepsis und Multiorganversagen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07962-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-07962-1_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-07963-8

  • Online ISBN: 978-3-662-07962-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation